Skip to main content
Kelsey C. Bertrand, MD, MSc, MBBS, FAAP
Kelsey C. Bertrand, MD, MSc, MBBS, FAAP

Kelsey C. Bertrand, MD, MSc, MBBS, FAAP

Assistant Member, St. Jude Faculty




BS - University of Guelph, Canada
MS - University of Toronto, Canada
MD - University of Queensland, Australia
Residency (Pediatrics) - Cleveland Clinic Children’s Hospital, Cleveland, Ohio
Fellowship (Pediatric Hematology-Oncology) - Baylor College of Medicine, Houston, Texas

Research Interests

  • Molecular and genomic heterogeneity within ependymoma
  • Understanding the underlying pathophysiology of ependymomas and high-grade gliomas
  • Mechanisms of resistance to therapy in CNS tumors

Selected Publications

Arabzade, A, et al. ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discovery 2021; epub ahead of press.

Stuckert AJ, Bertrand KC, Wang P, Smith A, Mack S. Weighing Ependymoma as an Epigenetic Disease. J Neurooncol 150(1):57-61, 2020.

Arabzade A, Stuckert AJ, Bertrand KC, Mack SC. The Role and contribution of Transcriptional Enhancers in Brain Cancer. Neuropathol and Appl Neurobiol 46(1):48-56, 2002.

Mack SC, Bertrand KC. Sub-group, sub-type and Cell-type Heterogeneity of Ependymoma. Cancer Cell 38(1):15-17, 2020.

Jane EP, Premkumar DR, Thambireddy S, Golbourn B, Agnihotri S, Bertrand KC, Mack SC, Myers MI, Chattopadhyay A, Taylor DL, Schurdak ME, Stern AM, Pollack IF. Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance. Mol Cancer Res 18(7): 1004-1017, 2020.

Krug B, De Jay B, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, cMcConechy MK, Chen C, Khazaei S, Koncar RF, Agnihotri S, Faury D, Ellezam B, Weil AG, Urisini-Siegel J, De Carvalho DD, Dirks PB, Lewis PW, Salomoni P, Lupien M, Arrowsmith C, Lasko PF, Garcia BA, Kleinman CL, Jabado N, Mack SC. Pervasive H3K27 acetylation eads to ERV expression and a therapeutic vulnerability in H3K27M gliomas. Cancer Cell 35(5):782-797, 2019.

Mack SC, Singh I, Wang X, Hirsch R, Wu Q, Villagomez R, Bernatchez JA, Zhu Z, Gimple RC, Kim LJY, Morton A, Lai S, Qui Z, Prager BC, Bertrand KC, Mah C, Zhou W, Lee C, Barnett GH, Vogelbaum M, Sloan AE, Chavez L, Bao S, Scacheri PC, Siquiera-Neto JL, Lin CY, Rich JN. Chromatin landscapes reveal developmentally encoded transcriptional states that define glioblastoma. Journal of Experimental Medicine 216(5):1071-1090, 2019.

Bertrand KC, Faria CC, Skowron P, Luck A, Garzia L, Wu X, Agnihotri S, Smith CA, Taylor MD, Mack SC, Rutka JT. A functional genomics approach to identify pathways of drug resistance in medulloblastoma. Acta Neuropathol Commun 6(1):146, 2018.

Khatua S, Mangum R, Bertrand KC, Zaky W, McCall D, Mack SC. Pediatric ependymoma: current treatment and newer therapeutic insights. Future Oncol 14(30):3175-3186, 2018.

Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature 553(7686):101-105, 2018.

Mack SC, Agnihotri S, Witt H, Shih DJ, Wang X, Zayne K, Barszczyk M, Ramaswamy V, Bertrand KC, Remke M, Yao Y, Ryzhova M, Massimi L, Grajkowska W, Lach B, Philips J, Gupta N, Weiss WA, Guha A,, Hawkins C, Croul S, Bader GD, Rutka JT, Zadeh G, Pfister SM, Korshunov A, Taylor MD. Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. Clin Cancer Res 21(16):3750-3758, 2015.

Faria CC, Agnihotri S, Mack SC, Golbourn BJ, Diaz RJ, Olsen S, Bryant M, Bebenek M, Wang X, Bertrand KC, Kushida M, Head R, Clark I, Dirks P, Smith CA, Taylor MD, Rutka JT. Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget 6(25):21718-21729, 2015.

Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT. Transcriptional profiling of GBM invasive genes identifies effective inhibitors of the LIM kinasecofilin pathway. Oncotarget 5(19):9382-95, 2014.

Mack SC, Bertrand KC, Wang K, Sin-Chan P, Ramaswamy V, Remke M, Zayne K, Merino D, Chan T, Huang A, Taylor MD. (2015). Basic Science of Pediatric Brain Tumors. M. Sova (Ed.), Pediatric Neuro-Oncology (pp. 59-68). Toronto: Springer Science. (Invited book chapter).

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jäger N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker-Cin H, Hutter S, Johann P, Bender S, Hovestadt V, Tzaridis R, Dubuc AM, Northcott PA, Peacock J, Bertrand KC, et al. Epigenetic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506(7489):445-450, 2014.

Pinkham MB, Bertrand KC, Olson S, Zarate D, Oram J, Pullar A, Foote MC. Hippocampal-sparing radiotherapy: the new standard of care for gliomas? Journal of Clinical Neuroscience 21(1):86-90, 2014.

Mack, SC, Witt, H, Wang X, Milde, T, Yao, Y, Bertrand KC, Korshunov, A, Pfister, SM, Taylor MD. Emerging Insights into the Ependymoma Epigenome. Brain Pathology 23(2):206-209, 2013.

Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20(2):143-157, 2011.

Bertrand KC, Mack SC, Northcott PA, Garzia L, Dubuc A, Pfister SM, Rutka JT, Weiss WA, Taylor MD. PCDH10 is a candidate tumour suppressor gene in Medulloblastoma. Childs Nerv Syst 27(8):1243-1249, 2011.

Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA Hypomethylation by Tumor Hypoxia. Epigenetics 2(2):119-125, 2007.

Last update: August 2021